Bli medlem
Bli medlem

Du är här

2016-03-31

Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies

geted Alpha Therapies

EXTON, Pa. and COURBEVOIE, France, 2016-03-31 18:00 CEST (GLOBE NEWSWIRE) --
Morphotek®, Inc., a subsidiary of Eisai Inc., and AREVA Med, the AREVA Group
medical subsidiary developing innovative therapies to fight cancer, announced
today that they have entered into a collaborative project to assess the
potential of a novel alpha radio-immunotherapy treatment in the fight against
cancer.

Under the terms of the agreement, Morphotek and AREVA Med will assess the
safety and efficacy profile of ontuxizumab conjugated with lead-212 (212Pb) in
preclinical studies. Ontuxizumab is a Morphotek investigational humanized
monoclonal antibody (mAb) that specifically targets the endosialin/tumor
endothelial marker 1 (TEM-1) antigen, whose expression is restricted to tumor
associated pericytes, tumor stromal cells and a subset of malignant cells. In
case of successful results, both companies agreed to further pursue drug
development.

“Opportunities to expand the use of our lead antibodies in new generation
formats, including radiopharmaceuticals, are a key corporate strategy as we
explore an array of therapeutic modalities for diseases expressing our top
priority pathways, such as endosialin/TEM-1,” commented Nicholas Nicolaides,
Morphotek’s President & CEO. “We are particularly excited to collaborate with
AREVA Med, who is specializing in alpha-based radiopharmaceuticals.”

Studies will be performed at AREVA Med’s new U.S. facility dedicated to the
production of 212Pb. This rare metal is used in Targeted Alpha Therapy (TAT),
an innovative oncology approach designed to target and kill cancer cells while
limiting damage to nearby healthy cells. Ontuxizumab will be conjugated using a
novel site-specific bioconjugation method developed by Macrocyclics, AREVA
Med’s subsidiary, and radiolabeled with 212Pb. The final compound is expected
to target the supporting microenvironment of solid tumors, and more
specifically tumor cell vasculature.

Patrick Bourdet, AREVA Med’s President CEO added: “We are delighted for this
new collaboration with Morphotek. The combination of their expertise using
highly specific vectors targeting cancer vasculature with AREVA Med’s
industrial and scientific capacity could result in several powerful and
innovative treatments to combat the disease.”

ABOUT MORPHOTEK
Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company
specializing in the development of protein and antibody products through the
use of a novel and proprietary gene evolution technology. The technology has
been successfully applied to a broad variety of cell lines and organisms to
yield genetically diverse offspring that are suitable for pharmaceutical
product development in the areas of antibody therapeutics, protein
therapeutics, product manufacturing, drug target discovery, and improved output
traits for commercial applications. The company is currently focusing its
platform on the development and manufacturing of therapeutic antibodies for the
treatment of cancer, inflammation and infectious disease. For more information,
please visit www.morphotek.com.

ABOUT EISAI INC.
At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd.,
we have a passionate commitment to patient care that is the driving force
behind our efforts to help address unmet medical needs. We are a fully
integrated pharmaceutical business with discovery, clinical, manufacturing and
marketing capabilities. Our key areas of commercial focus include oncology and
specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To
learn more about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai’s
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based programs.

MORE ABOUT AREVA Med
AREVA Med is the AREVA group Medical subsidiary formed in 2009 to develop new
therapies to fight cancer. AREVA Med has developed a unique process to extract
lead-212 (212Pb), a rare metal used in targeted alpha therapy (TAT), a novel
approach which targets and destroys cancer cells, while limiting the impact on
nearby healthy cells. AREVA Med collaborates with world-renowned scientific
partners, and formed a strategic global alliance with Roche in 2012, to create
a new advanced alpha radioimmunotherapy platform. For more information:
www.arevamed.com. Follow @AREVAmed on Twitter.

Press Contacts

Morphotek
Investor Inquiries
Rod Dausch
Morphotek, Inc.
610-423-6111

Media Inquiries
Diana Martens
Morphotek, Inc.
610-423-6085

AREVA Med
Alison Tise
(301) 841-1673
Alison.Tise@areva.com
@AREVAmed

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.